Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, ...

Condé Nast Traveler readers believe this major US city is the end-all-be-all for shopping destinations in the country.

F1 news, rumours and gossip: Formula 1 latest updates on teams, driver transfer market and contracts Follow the latest news from the world of Formula 1 during the off-season ahead of the 2026 campaign ...